In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae : Application to Breakpoint Determinations
- 1 September 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (9), 2375-2379
- https://doi.org/10.1128/aac.42.9.2375
Abstract
The in vivo activities of amoxicillin and amoxicillin-clavulanate against 17 strains of Streptococcus pneumoniae with penicillin MICs of 0.12–8.0 mg/liter were assessed in a cyclophosphamide-induced neutropenic murine thigh infection model. Renal impairment was produced by administration of uranyl nitrate to prolong the amoxicillin half-life in the mice from 21 to 65 min, simulating human pharmacokinetics. Two hours after thigh infection with 105 to 106 CFU, groups of mice were treated with 7 mg of amoxicillin per kg of body weight alone or combined with clavulanate (ratio, 4:1) every 8 h for 1 and 4 days. There was an excellent correlation between the MIC of amoxicillin (0.03 to 5.6 mg/liter) and (i) the change in log10 CFU/thigh at 24 h and (ii) survival after 4 days of therapy. Organisms for which MICs were 2 mg/liter or less were killed at 1.4 to 4.2 and 1.6 to 4.1 log10 CFU/thigh at 24 h by amoxicillin and amoxicillin-clavulanate, respectively. The four strains for which MICs were >4 mg/liter grew 0.2 to 2.6 and 0.6 to 2.3 logs at 24 h despite therapy with amoxicillin and amoxicillin-clavulanate, respectively. Infection was uniformly fatal by 72 h in untreated mice. Amoxicillin therapy resulted in no mortality with organisms for which MICs were 1 mg/liter or less, 20 to 40% mortality with organisms for which MICs were 2 mg/liter, and 80 to 100% mortality with organisms for which MICs were 4.0–5.6 mg/liter. Lower and higher doses (0.5, 2, and 20 mg/kg) of amoxicillin were studied against organisms for which MICs were near the breakpoint. These studies demonstrate that a reduction of 1 log10 or greater in CFU/thigh at 24 h is consistently observed when amoxicillin levels exceed the MIC for 25 to 30% of the dosing interval. These studies would support amoxicillin (and amoxicillin-clavulanate) MIC breakpoints of 1 mg/liter for susceptible, 2 mg/liter for intermediate, and 4 mg/liter for resistant strains of S. pneumoniae.Keywords
This publication has 19 references indexed in Scilit:
- Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory seasonDiagnostic Microbiology and Infectious Disease, 1997
- Bacteriologic Response to Oral Cephalosporins: Are Established Susceptibility Breakpoints Appropriate in the Case of Acute Otitis Media?The Journal of Infectious Diseases, 1997
- Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibilityThe Pediatric Infectious Disease Journal, 1996
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- MENINGITIS WITH BETA-LACTAM-RESISTANT STREPTOCOCCUS PNEUMONIAEThe Pediatric Infectious Disease Journal, 1993
- Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitisThe Pediatric Infectious Disease Journal, 1993
- Amoxicillin/Clavulanic AcidDrugs, 1990
- IMIPENEM-CILASTATIN THERAPY IN A CHILD WITH MENINGITIS CAUSED BY A MULTIPLY RESISTANT PNEUMOCOCCUSThe Pediatric Infectious Disease Journal, 1989
- Experimental Infection with Streptococcus pneumoniae in Mice: Correlation of in Vitro Activity and Pharmacokinetic Parameters with in Vivo Effect for 14 CephalosporinsThe Journal of Infectious Diseases, 1986
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981